ライフサイエンスコーパス: eye disease

1 ing, or differing demographics of those with eye disease.

2 tivation and initiation of immune-driven dry eye disease.

3 cifically regulated during immune-driven dry eye disease.

4 tional supplements for primary prevention of eye disease.

5 luding cancers, atherosclerosis and blinding eye disease.

6 uringly and drive pathogenesis of a blinding eye disease.

7 sic and clinical research of human inherited eye disease.

8 eening test results and visually significant eye disease.

9 gists in the management and treatment of dry eye disease.

10 formation that remained depressed during dry eye disease.

11 opment of regenerative medical approaches to eye disease.

12 001) as associated with visually significant eye disease.

13 ose, classify, and grade the severity of dry eye disease.

14 classification, and severity grading of dry eye disease.

15 ptoms or corneal fluorescein staining in dry eye disease.

16 peutic lead toward the treatment of diabetic eye disease.

17 figitumumab, the IGF-1 inhibitor, causes dry eye disease.

18 in treating ocular inflammation such as dry eye disease.

19 he importance of retinol metabolism in human eye disease.

20 samples and some patient samples with known eye disease.

21 ve treatments for patients with inflammatory eye disease.

22 elopment of future therapeutics for diabetic eye disease.

23 an be useful in understanding vessel-related eye disease.

24 dysfunction (MGD) is a primary cause of dry eye disease.

25 ly T-cell-mediated immunopathogenesis of dry eye disease.

26 effectiveness in future studies of diabetic eye disease.

27 , where an anti-VEGF agent was used to treat eye disease.

28 l for assessing novel interventions to treat eye disease.

29 col/propylene glycol in the treatment of dry eye disease.

30 tear secretion and prevent experimental dry eye disease.

31 d summarizes the role of inflammation in dry eye disease.

32 ty in the evaluation and grading of diabetic eye disease.

33 abnormal Bruch Membrane thickness, a sign of eye disease.

34 rrent uveitis, as well as other inflammatory eye diseases.

35 h human orthologs previously associated with eye diseases.

36 approach for allergic conjunctivitis and dry eye diseases.

37 delivered 12 may be efficacious in human dry eye diseases.

38 and autoimmune diseases, lung diseases, and eye diseases.

39 and is reported to play pathogenic roles in eye diseases.

40 athology images, and external photographs of eye diseases.

41 ngoing systemic severe pathology, asthma and eye diseases.

42 ations in bestrophin 1 (BEST1) cause certain eye diseases.

43 tential novel therapeutic target in fibrotic eye diseases.

44 tive impairment, intracranial pathologies or eye diseases.

45 services by SEP persist among US adults with eye diseases.

46 ing the diagnosis and treatment of inherited eye diseases.

47 d their enzymatic metabolites in neovascular eye diseases.

48 a novel etiologic discovery for these common eye diseases.

49 egulating pathological neovascularization in eye diseases.

50 a common treatment strategy for neovascular eye disease, a major cause of vision loss in diabetic re

51 a tertiary care referral center for diabetic eye disease, a retrospective, longitudinal cohort study

52 tinopathy (PDR) in 31% and advanced diabetic eye disease (ADED) in 3% (n = 100).

53 at presentation, an 80% reduction in second eye disease (adjusted HR, 0.2; 95% CI, 0.1-0.5; P = 0.00

54 nd are deficient in dry eye, the most common eye disease affecting at least 5% of the world's populat

55 n trials and reviews of the 4 most prevalent eye diseases (age-related macular degeneration [AMD], ca

56 describe the entity of Lyonization in ocular eye diseases, along with its clinical and counseling imp

57 Of identified patients, 38% had eye disease and 12% presented with other serious manifes

58 y congenital glaucoma (PCG) is a devastating eye disease and an important cause of childhood blindnes

59 The adjusted odds ratio for dry eye disease and anxiety was 2.8 (95% confidence interval

60 ritical to early detection and prevention of eye disease and associated morbidity and mortality; howe

61 tival epitheliopathies that may occur in dry eye disease and contact lens wear.

62 human ocular surface in mild to moderate dry eye disease and controls.

63 For dry eye disease and depression, the odds ratio was 2.9 (95%

64 Separate odds ratios were calculated for dry eye disease and each of anxiety and depression.

65 stically significant association between dry eye disease and each of depression and anxiety.

66 idosis, somatic mutations in LCAT cause fish eye disease and familial LCAT deficiency.

67 ) T-cell subsets play a role in the blinding eye disease and in controlling virus replication.

68 , dopamine and melatonin), may contribute to eye disease and pathology.

69 odds ratios were also calculated between dry eye disease and rheumatoid arthritis, a systemic disease

70 LASIK, further reducing the incidence of dry eye disease and subsequent degradation in quality of lif

71 oteins represent a potential therapy for dry eye disease and the strategy of ELP-mediated phase separ

72 can be further developed as a model for dry eye disease and therapeutic evaluation.

73 with inaccurate self-report underestimating eye disease and treatment.

74 a standardized way to evaluate the impact of eye disease and/or visual rehabilitation on sustained si

75 will provide estimates of the progression of eye diseases and incidence of blindness, visual impairme

76 HR ligands as future therapeutic options for eye diseases and possibly also for other scarring condit

77 rt for eye health research, and awareness of eye diseases and risk factors.

78 Implications for RPE-related eye diseases and the acne drug isotretinoin (a retinoid

79 Many Americans were unaware of important eye diseases and their behavioral or familial risk facto

80 eases like corneal transplant rejection, dry eye disease, and allergy.

81 evidence base for treatments in inflammatory eye disease, and in particular uveitis, from a historica

82 une mediator in many diseases, including dry-eye disease, and its inhibition is clinically efficaciou

83 Millions of Americans suffer from dry eye disease, and there are few effective therapies capab

84 The aging population is at risk of common eye diseases, and routine eye examinations are recommend

85 d according to ICD-9 diagnosis codes for dry eye disease, anxiety, and depression.

86 ract, glaucoma, diabetic retinopathy and dry eye disease are common with high prevalence in Jordan.

87 These eye diseases are retinal degeneration 1 (Pde6b(rd1)), re

88 Individuals with age-related eye disease (ARED) need to use eye care services for det

89 f approaches to the amelioration of blinding eye diseases associated with visual cycle defects.

90 of eye disease was 60 months and duration of eye disease at baseline 145 months.

91 ) is an apicomplexan parasite that can cause eye disease, brain disease, and death, especially in con

92 t age over 80 years, its contribution to the eye disease burden is expected to be remarkably high.

93 ) have transformed the treatment of diabetic eye disease but have proven inadequate for treating NV,

94 cated in the pathogenesis and progression of eye diseases, but it remains unclear whether activation

95 a promising tool in the diagnosis of various eye diseases, but the available diagnostic evidence has

96 op priority (P = 0.02), and whether diabetic eye disease can be seen with an examination (P = 0.05).

97 Genetic testing for inherited eye diseases can be costly but has many benefits to pati

98 d as none, moderate, or severe VI) and major eye diseases (cataract, uncorrected refractive error, gl

99 C-HA/PTX3 is a novel approach to prevent dry eye disease caused by cGVHD and allow us to test its saf

100 dystrophy (BCD) is a recessive degenerative eye disease caused by germline mutations in the CYP4V2 g

101 Butterfly-shaped pigment dystrophy is an eye disease characterized by lesions in the macula that

102 sa (RP) is a group of inherited degenerative eye diseases characterized by mutations in the genetic s

103 al testing, and retinal imaging at a genetic eye disease clinic of a tertiary referral eye hospital.

104 activation contributed to serum-induced dry eye disease, cobra venom factor was used to deplete comp

105 ed within the 6-year follow-up of the Nakuru Eye Disease Cohort in central Kenya and included 300 adu

106 ry 7, 2013, to March 12, 2014) of the Nakuru Eye Disease Cohort in Kenya, 1460 adults (2920 eyes) 55

107 m the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study.

108 ithm in detecting sight-threatening diabetic eye disease compared with the reading center interpretat

109 udinal population-based study of age-related eye diseases conducted in the city and township of Beave

110 epository and patient registry for inherited eye diseases coupled to phenotypic descriptors and molec

111 Dry eye disease (DED) affects millions of people worldwide.

112 estimates of the prevalence of diagnosed dry eye disease (DED) and associated demographics among US a

113 severity of ocular pain in patients with dry eye disease (DED) and evaluate factors associated with p

114 ving visual performance in patients with dry eye disease (DED) and to determine clinical predictors o

115 to compare patient-reported symptoms of dry eye disease (DED) as assessed by the Ocular Surface Dise

116 A majority of experimental data on dry eye disease (DED) immunopathogenesis have been derived f

117 Dry eye disease (DED) is a common ocular disorder affecting

118 Dry eye disease (DED) is a highly prevalent, ocular disorder

119 Dry eye disease (DED) is common, but little is known about f

120 Dry eye disease (DED) is multifactorial, affecting 5-34 % of

121 Dry eye disease (DED) represents a heterogeneous group of co

122 ssociation between serum metabolites and dry eye disease (DED) using a hypothesis-free metabolomics a

123 itiate a 5-year natural history study of dry eye disease (DED) using objectively assessed and patient

124 glaucoma, diabetic retinopathy (DR) and dry eye disease (DED) was assessed.

125 Diagnostic tests for dry eye disease (DED), including ocular surface disease inde

126 The immunopathogenic mechanisms of dry eye disease (DED), one of the most common ophthalmic con

127 ll-mediated inflammation associated with dry eye disease (DED).

128 iscordance between symptoms and signs in dry eye disease (DED).

129 ating the ocular surface autoimmunity in dry eye disease (DED).

130 ry effector cells in the pathogenesis of dry eye disease (DED).

131 ontribution to the immunopathogenesis of dry eye disease (DED).

132 riacylglyceride (fish oil), for treating dry eye disease (DED).

133 nist developed to reduce inflammation in dry eye disease (DED).

134 ntion designed to improve glaucoma and other eye disease detection and follow-up care in high-risk po

135 zon, supplemental health insurance coverage, eye disease diagnoses, and low vision/blindness at basel

136 h and without diabetes, health insurance, an eye disease diagnosis, and higher income were associated

137 Ocular syphilis is an inflammatory eye disease due to Treponema pallidum infection.

138 Herpetic eye disease (due to herpes simplex and herpes zoster) is

139 e on the ocular surface of patients with dry eye disease during 60 days of intervention.

140 (MGD) is the major cause of evaporative dry eye disease (EDED) and dysfunction is widely thought to

141 amine whether HC-HA/PTX3 could attenuate dry eye disease elicited by cGVHD.

142 erly persons with DM or frequently occurring eye diseases, especially for DM, remain far below recomm

143 as a model of population-based screening for eye disease, FDT perimetry lacks both sensitivity and sp

144 ied diabetic retinopathy and AMD as priority eye diseases for the prevention of vision loss in develo

145 ces in understanding the pathogenesis of dry eye disease has revealed that inflammation is a core dri

146 ments in anti-VEGF treatment for neovascular eye disease have improved visual outcomes and changed th

147 ion and the pathophysiology of many blinding eye diseases, here we investigated whether the absence o

148 S, MM, WM and AL amyloidosis with subsequent eye diseases identified from the Swedish patient registe

149 measures included, from NHANES, age-related eye diseases (ie, age-related macular degeneration [AMD]

150 ccurate and efficient means of screening for eye disease in an American Indian/Alaskan Native populat

151 with the development or worsening of thyroid eye disease in approximately 15% to 20% of patients.

152 udinal data from population-based studies of eye disease in sub-Saharan-Africa are available.

153 Inflammation was induced to mimic dry eye disease in the coculture model system.

154 could help support the diagnosis of herpetic eye disease in these patients.

155 to estimate the incidence and progression of eye disease in this population.

156 network of epidemiological studies of common eye diseases in adults across Europe.

157 cidence of blindness, visual impairment, and eye diseases in an adult Kenyan population.

158 sk for the development of common age-related eye diseases in older age.

159 henotype and genotype survey of three common eye diseases in the collection of JAX mice strains at Th

160 he diagnosis and management of patients with eye diseases in which the choroid is affected.

161 Ds), visual acuity (VA) change, and diabetic eye disease incidence and progression.

162 ditionally hindered progress in inflammatory eye disease including small target populations, heteroge

163 Two insults often underlie a variety of eye diseases including glaucoma, optic atrophy, and reti

164 zation in patients with blinding neovascular eye diseases, including macular degeneration.

165 Neovascular eye diseases, including retinopathy of prematurity, diab

166 tralizing antibodies protect mice from HSV-1 eye disease, indicating the critical role of HVEM in HSV

167 In the context of a blinding eye disease, indirect activation of PDGFRalpha results i

168 are associated with heart-rate disturbance, eye disease, intellectual disability, gastric problems,

169 Dry eye disease is a major public health problem that affect

170 A phase 1 study has reported that dry eye disease is the most common adverse effect of human e

171 Dry eye disease is the prominent ocular sequel of cGVHD and

172 Visual impairment related to eye diseases is not reversible with spectacles.

173 mental health may be important correlates of eye disease knowledge and eye health information exposur

174 arch can be impaired in patients with common eye diseases like glaucoma and age-related macular degen

175 ce, to our knowledge, of its contribution to eye disease, likely through a gain-of-function mechanism

176 E The association between atopy and herpetic eye disease may be explained by various factors, includi

177 Ophthalmic care for dry eye disease may be needed when patients with cancer unde

178 ion screening for refractive error and early eye disease may reduce or prevent a high proportion of i

179 n screening for refractive error and related eye diseases may prevent a high proportion of preschool

180 eration and germinal center formation in dry eye disease mice, suggesting that a stable Ag-dependent

181 ics targeting the VEGF pathway in cancer and eye disease might be expanded to promote neuronal health

182 mentally-timed induction of Arf resulting in eye disease mimicking the persistent hyperplastic primar

183 years) and elderly control subjects without eye disease (n = 10; aged 51-79 years) were studied with

184 a multitude of more severe symptoms such as eye disease, neonatal infection, and, in rare cases, enc

185 maging has the potential to be used to study eye diseases noninvasively.

186 serving as controls or patients with thyroid eye disease, nonspecific orbital inflammation, or granul

187 acuity in a number of previously untreatable eye diseases, of which the main are age-related macular

188 ive patients were registered due to diabetic eye disease.Of those 24 reported by the GP of NPL vision

189 Univariate analysis identified history of eye disease or diabetes mellitus (P < .001), visual acui

190 HZO recurrence was defined as any recurrent eye disease or rash 90 days or more after quiescence of

191 5-year recurrence rates for either recurrent eye disease or rash were 8%, 17%, and 25%, respectively.

192 apy to complement VEGF or VEGFR2 blockade in eye disease or solid tumor growth.

193 and those treated with systemic steroids for eye disease (OR, 10.1; 95% CI,1.60-64.0; P = .01).

194 ions of choroidal vessel disease to diabetic eye disease pathogenesis, prognosis, and treatment respo

195 uate the prevalence of patients with thyroid eye disease presenting with apparent unilateral proptosi

196 Acanthamoeba keratitis, a rare eye disease primarily affecting contact lens wearers, is

197 Immune-driven dry eye disease primarily affects women; the cause for this

198 In these 21 eyes, disease-related choroidal inflammation on ICGA was

199 Despite treatment advances, diabetic eye disease remains a leading cause of visual acuity (VA

200 However, the role of PMNs in dry eye disease remains unexplored.

201 opathy (DR) in the Singapore Epidemiology of Eye Diseases (SEED) Study.

202 years or younger and 108 individuals without eye disease serving as controls.

203 clinical trial to treat currently incurable eye diseases severely affecting cone vision despite reta

204 y corneal inoculation with HSV-1 had reduced eye disease, shedding, and latent infection.

205 f retinal tissue from patients with diabetic eye disease shows that HIF-1alpha and ANGPTL4 localize t

206 The Systemic Treatment for Eye Diseases (SITE) Cohort Study suggested long-term saf

207 m the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) cohort study.

208 presence and severity using the Age-Related Eye Disease Study (AREDS) 9-step scale.

209 a were age over 50, diagnosis of Age-Related Eye Disease Study (AREDS) category 2 and 3, naive neovas

210 The Age-Related Eye Disease Study (AREDS) demonstrated that antioxidant

211 Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitam

212 The Age-Related Eye Disease Study (AREDS) formulation for the treatment

213 l rankings of FAF images and the Age-Related Eye Disease Study (AREDS) grading scheme of correspondin

214 We observed the Age-Related Eye Disease Study (AREDS) participants for an additional

215 y population and to validate the Age-Related Eye Disease Study (AREDS) simplified severity scale in A

216 sand participants drawn from the Age-Related Eye Disease Study (AREDS) were chosen for genotyping.

217 reanalyzed data derived from the Age-Related Eye Disease Study (AREDS), receiving data prepared by th

218 ble participants in the baseline Age-Related Eye Disease Study (AREDS).

219 0 samples from five cohorts: the Age-Related Eye Disease Study (AREDS); the KORA study ('Cooperative

220 rticipants of the Carotenoids in Age-Related Eye Disease Study (CAREDS) (aged 54 to <75 years) with a

221 n the TwinsUK and Carotenoids in Age-Related Eye Disease Study (CAREDS) cohorts.

222 The Herpetic Eye Disease Study (HEDS) I showed a significant benefit

223 Between 1993 and 1997, the Herpetic Eye Disease Study (HEDS) randomized 703 participants wit

224 nd AMD progression data from the Age-Related Eye Disease Study 1 were used to simulate the long-term

225 fundus reflex photographs in the Age-Related Eye Disease Study 2 (AREDS2) and compared reproducibilit

226 The Age-Related Eye Disease Study 2 (AREDS2) assessed the value of subst

227 eneration (nonadvanced AMD) from Age-Related Eye Disease Study 2 (AREDS2) color fundus photography (C

228 Using the Age-Related Eye Disease Study 2 (AREDS2) grading system and multimod

229 ew provides a perspective on the Age-related Eye Disease Study 2 (AREDS2) including a summary of the

230 The primary purpose of the Age-Related Eye Disease Study 2 (AREDS2) is to evaluate the efficacy

231 of peripheral retinal changes in Age-Related Eye Disease Study 2 (AREDS2) participants with at least

232 The Age-Related Eye Disease Study 2 (AREDS2) was a prospective multicent

233 SIGN, SETTING, AND PATIENTS: The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-mask

234 , SETTING, AND PARTICIPANTS: The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, randomized,

235 ssociation study (DeePAS) in the Age-Related Eye Disease Study 2 (AREDS2), followed by replication us

236 and/or omega-3 fatty acids, the Age-Related Eye Disease Study 2 (AREDS2), for treatment of AMD and c

237 d randomized clinical trial (the Age-Related Eye Disease Study 2 [AREDS2]), retinal specialists in 82

238 Age-Related Eye Disease Study 2 Ancillary SD OCT study participants

239 (mean age, 68.6 years) from the Age-Related Eye Disease Study 2 Ancillary SDOCT Study.

240 onitoring of the Eye study at 44 Age-Related Eye Disease Study 2 clinical centers.

241 nd visual outcomes data from the Age-Related Eye Disease Study 2 Home Monitoring of the Eye study, tr

242 SIGN, SETTING, PARTICIPANTS: The Age-Related Eye Disease Study 2 is a multicenter, double-masked rand

243 red to be step 1 (normal) on the Age-Related Eye Disease Study 9-step AMD classification system based

244 the findings from the Multi-Ethnic Pediatric Eye Disease Study and Baltimore Pediatric Eye Disease St

245 308 participants in the multicenter Herpetic Eye Disease Study between 1992 and 1998 (48% female; 85%

246 is and staging, according to the Age-Related Eye Disease Study classification scheme.

247 he National Institutes of Health Age-related Eye Disease Study data set was evaluated.

248 agreement with the gold standard Age-related Eye Disease Study data set.

249 of circle C1 (diameter 125 mum; Age-Related Eye Disease Study grading protocol).

250 alized Reading Center, using the Age-Related Eye Disease Study grading system.

251 The Multi-Ethnic Pediatric Eye Disease Study is a population-based evaluation of th

252 Sera of 134 participants in the Age-related Eye Disease Study were analyzed for anti-retinal AAbs by

253 alized Reading Center, using the Age-Related Eye Disease Study-2 grading system.

254 ic Eye Disease Study and Baltimore Pediatric Eye Disease Study.

255 hnicities from the Singapore Epidemiology of Eye Disease study.

256 We aimed to validate the Age-Related Eye Diseases Study (AREDS) simplified severity scale of

257 The Singapore Epidemiology of Eye Diseases Study is a population-based trial in which

258 oc analysis of the Singapore Epidemiology of Eye Diseases study, a population-based study of 10033 pa

259 oc analysis of the Singapore Epidemiology of Eye Diseases study, a population-based study of particip

260 diabetes from the Singapore Epidemiology of Eye Diseases Study, of whom 547 (35.8%) had DR.

261 al population AOR, 1.34 [95% CI, 1.33-1.35]; eye-disease subsample AOR, 1.37 [95% CI, 1.34-1.39]).

262 al population AOR, 1.24 [95% CI, 1.22-1.26]; eye-disease subsample AOR, 1.45 [95% CI, 1.42-1.49]), an

263 matter (AOR, 1.70), and respondents from the eye-disease subsample who had an eye care visit also wer

264 rs and, in turn, preventing key signs of dry eye disease such as aqueous tear secretion, conjunctival

265 hat pathology of age-associated degenerative eye diseases such as adult macular degeneration (AMD), g

266 Vision impairment and major age-related eye diseases such as cataract, DR, and glaucoma are asso

267 LTBP2 have been found in humans with genetic eye diseases such as congenital glaucoma and microsphero

268 ion interferes with the assessment of common eye diseases such as glaucoma and comes on top of the de

269 Ocular neovascularisation underlies blinding eye diseases such as retinopathy of prematurity, prolife

270 lar photoreceptors cause vision loss in many eye diseases, such as age-related macular degeneration a

271 l networks (ANNs) have been used to classify eye diseases, such as diabetic retinopathy (DR) and glau

272 Photoreceptors are damaged in many common eye diseases, such as macular degeneration, retinal deta

273 rst consists of 18 waxes and shows different eyes diseases, such as neoplasm and tenonitis, and ophth

274 mechanisms of refractive surgery induced dry eye disease, surgical options, including modification of

275 Thyroid eye disease (TED) has been found to reduce quality of li

276 Thyroid eye disease (TED) is a degenerative disease that manifes

277 ween patients with acute and chronic thyroid eye disease (TED).

278 or ocular infections, wound healing, and dry-eye disease that affect the vision of millions worldwide

279 Acanthamoeba keratitis is a debilitating eye disease that requires effective topical drug therapy

280 ith diabetes have sight-threatening diabetic eye disease, the IRIS algorithm positive predictive valu

281 nsitivity due to normal aging or age-related eye diseases, thus potentially accelerating visual impai

282 ivariate analysis found visually significant eye disease to be associated (P < .001; receiver operati

283 Genome-wide Association Studies (GWASs) for eye diseases/traits have delivered a number of novel fin

284 atment, birth control, cancer treatment, and eye disease treatment.

285 Median age at onset of eye disease was 60 months and duration of eye disease at

286 Dry eye disease was defined from the validated Short Questio

287 Dry eye disease was diagnosed if participants had at least 1

288 High incidence of mild to moderate dry eye disease was observed in both groups 1 month postoper

289 Complete evaluation of dry eye disease was performed at 1 and 6 months postoperativ

290 ng a preclinical model of IL-17-mediated dry eye disease, we demonstrate that upon encountering both

291 t, glaucoma, significant cataract, and major eye diseases, were selected from the population-based Si

292 ding the epidemiologic factors of infectious eye diseases, which could better inform eye health care

293 large goiters or moderate to severe thyroid eye disease who cannot be treated using antithyroid drug

294 lenges in the fight against HIV/AIDS-related eye disease will involve identifying additional factors

295 dence and risk factors of glaucoma and other eye diseases will be evaluated, as well as their impact

296 655 consecutive patients affected by thyroid eye disease with a minimum follow-up of 10 years was rev

297 ioretinopathy (CSCR) is a vision-threatening eye disease with no validated treatment and unknown path

298 Asymmetric thyroid eye disease with the appearance of unilateral exophthalm

299 e: To assess the association of VI and major eye diseases with mobility and independence (M&I) in a C

300 onjunctivitis (AHC) is a painful, contagious eye disease, with millions of cases in the last decades.